RBC Capital Defending Mirum Pharmaceuticals (MIRM) Amid 15% Drop: 'Buying Opportunity Ahead of Multiple De-risked Catalysts'
Tweet Send to a Friend
RBC Capital analyst Joe Kim reiterated an Outperform rating and $128.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
